| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/HEAD.13064 |
| P698 | PubMed publication ID | 28233915 |
| P50 | author | Debbie Hay | Q37829061 |
| Christopher Walker | Q37829052 | ||
| P2860 | cites work | An amylin receptor is revealed following co-transfection of a calcitonin receptor with receptor activity modifying proteins-1 or -3 | Q22009905 |
| Visualization of the calcitonin receptor-like receptor and its receptor activity-modifying proteins during internalization and recycling | Q22254563 | ||
| Characterization of the human calcitonin gene-related peptide receptor subtypes associated with receptor activity-modifying proteins | Q24304926 | ||
| Identification of multiple human calcitonin receptor isoforms: heterologous expression and pharmacological characterization | Q24319098 | ||
| RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor | Q24323946 | ||
| International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors | Q28201576 | ||
| Agonist-promoted internalization of a ternary complex between calcitonin receptor-like receptor, receptor activity-modifying protein 1 (RAMP1), and beta-arrestin | Q28215231 | ||
| Immunohistochemical localization of calcitonin receptor-like receptor and receptor activity-modifying proteins in the human cerebral vasculature | Q28215715 | ||
| Calcitonin gene-related peptide: physiology and pathophysiology | Q28249298 | ||
| Vasoactive peptide release in the extracerebral circulation of humans during migraine headache | Q28265001 | ||
| The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes | Q28267757 | ||
| Post-endocytic sorting of calcitonin receptor-like receptor and receptor activity-modifying protein 1 | Q28289037 | ||
| Cloning, characterization and central nervous system distribution of receptor activity modifying proteins in the rat | Q28567431 | ||
| Hydrops fetalis, cardiovascular defects, and embryonic lethality in mice lacking the calcitonin receptor-like receptor gene | Q28592688 | ||
| Migraine biomarkers in cerebrospinal fluid: A systematic review and meta-analysis | Q30251901 | ||
| Role of calcitonin gene-related peptide in light-aversive behavior: implications for migraine | Q30496689 | ||
| Pharmacological characterization of MK-0974 [N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide], a potent and orally active calcitonin gene-relate | Q30838883 | ||
| Pharmacological properties of MK-3207, a potent and orally active calcitonin gene-related peptide receptor antagonist | Q33523240 | ||
| Cerebellar distribution of calcitonin gene-related peptide (CGRP) and its receptor components calcitonin receptor-like receptor (CLR) and receptor activity modifying protein 1 (RAMP1) in rat. | Q33735468 | ||
| Molecular aspects and natural source of procalcitonin | Q33760702 | ||
| The delta e13 isoform of the calcitonin receptor forms a six-transmembrane domain receptor with dominant-negative effects on receptor surface expression and signaling. | Q34063180 | ||
| BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study | Q34155864 | ||
| Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial | Q34442510 | ||
| Neuronal receptor activity-modifying protein 1 promotes energy expenditure in mice | Q34718618 | ||
| Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial | Q34889352 | ||
| Localization of CGRP receptor components, CGRP, and receptor binding sites in human and rhesus cerebellar cortex | Q34897152 | ||
| Calcitonin gene-related peptide (CGRP): a new target for migraine | Q35358428 | ||
| Localization of CGRP, CGRP receptor, PACAP and glutamate in trigeminal ganglion. Relation to the blood-brain barrier | Q35477839 | ||
| Calcitonin gene-related peptide (CGRP) and its receptor components in human and rat spinal trigeminal nucleus and spinal cord at C1-level | Q35766483 | ||
| A second trigeminal CGRP receptor: function and expression of the AMY1 receptor. | Q35777253 | ||
| Structural Basis for Receptor Activity-Modifying Protein-Dependent Selective Peptide Recognition by a G Protein-Coupled Receptor | Q35856565 | ||
| Consequences of splice variation on Secretin family G protein-coupled receptor function | Q36153242 | ||
| Pharmacological characterization of rat amylin receptors: implications for the identification of amylin receptor subtypes. | Q36153252 | ||
| Central nervous system binding sites for calcitonin and calcitonin gene-related peptide | Q36472901 | ||
| Neuropeptide deficient mice have attenuated nociceptive, vascular, and inflammatory changes in a tibia fracture model of complex regional pain syndrome | Q36527054 | ||
| Receptor activity-modifying protein-dependent impairment of calcitonin receptor splice variant Δ(1-47)hCT((a)) function | Q36629283 | ||
| An allosteric role for receptor activity-modifying proteins in defining GPCR pharmacology | Q36907408 | ||
| What makes a CGRP2 receptor? | Q36916945 | ||
| CGRP antagonists: unravelling the role of CGRP in migraine | Q36982809 | ||
| CGRP in the trigeminovascular system: a role for CGRP, adrenomedullin and amylin receptors? | Q37337815 | ||
| Genetic enhancement of calcitonin gene-related Peptide-induced central sensitization to mechanical stimuli in mice. | Q37363843 | ||
| The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs | Q37606694 | ||
| Expression in brain of a messenger RNA encoding a novel neuropeptide homologous to calcitonin gene-related peptide | Q48375356 | ||
| Bench to bedside advances in the 21st century for primary headache disorders: migraine treatments for migraine patients | Q48495487 | ||
| Mapping the calcitonin receptor in human brain stem | Q48881416 | ||
| Premonitory and nonheadache symptoms induced by CGRP and PACAP38 in patients with migraine. | Q51328299 | ||
| Plasma calcitonin gene-related peptide in diagnosing and predicting paediatric migraine. | Q51805228 | ||
| Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. | Q52856000 | ||
| Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura | Q57024171 | ||
| Long-Term Tolerability of Telcagepant for Acute Treatment of Migraine in a Randomized Trial | Q57197723 | ||
| Targeting a family B GPCR/RAMP receptor complex: CGRP receptor antagonists and migraine | Q37922799 | ||
| Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development | Q38121126 | ||
| Monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity | Q38196732 | ||
| Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine | Q38222817 | ||
| Identification of an orphan receptor gene as a type 1 calcitonin gene-related peptide receptor | Q38287711 | ||
| Distribution of novel CGRP1 receptor and adrenomedullin receptor mRNAs in the rat central nervous system | Q38336498 | ||
| Calcitonin gene-related peptide and migraine | Q38427034 | ||
| Amylin: Pharmacology, Physiology, and Clinical Potential | Q38526856 | ||
| Targeting CGRP: A New Era for Migraine Treatment | Q38542176 | ||
| The Journey to Establish CGRP as a Migraine Target: A Retrospective View. | Q38561443 | ||
| Diverse Physiological Roles of Calcitonin Gene-Related Peptide in Migraine Pathology: Modulation of Neuronal-Glial-Immune Cells to Promote Peripheral and Central Sensitization | Q38873658 | ||
| Wiping Out CGRP: Potential Cardiovascular Risks | Q38875005 | ||
| CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment. | Q39193269 | ||
| In vivo quantification of calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus monkey and human brain using the positron emission tomography tracer [11C]MK-4232. | Q39221671 | ||
| Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion | Q39703608 | ||
| Reply to comment on: A second trigeminal CGRP receptor: function and expression of the AMY1 receptor | Q39814264 | ||
| Localization of calcitonin receptor-like receptor and receptor activity modifying protein 1 in enteric neurons, dorsal root ganglia, and the spinal cord of the rat. | Q40388098 | ||
| Model for alternative RNA processing in human calcitonin gene expression | Q40419568 | ||
| An assessment of the anabolic skeletal actions of the common-region peptides derived from the CGRP and calcitonin prohormones | Q41618159 | ||
| Neuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors | Q41629862 | ||
| Calcitonin and amylin receptor peptide interaction mechanisms. INSIGHTS INTO PEPTIDE-BINDING MODES AND ALLOSTERIC MODULATION OF THE CALCITONIN RECEPTOR BY RECEPTOR ACTIVITY-MODIFYING PROTEINS. | Q41986597 | ||
| Type II Turn of Receptor-bound Salmon Calcitonin Revealed by X-ray Crystallography. | Q42103047 | ||
| CGRP and adrenomedullin binding correlates with transcript levels for calcitonin receptor-like receptor (CRLR) and receptor activity modifying proteins (RAMPs) in rat tissues | Q42115964 | ||
| Autoradiographic localization of calcitonin gene-related peptide binding sites in human and rat brains | Q42152515 | ||
| CL/RAMP2 and CL/RAMP3 produce pharmacologically distinct adrenomedullin receptors: a comparison of effects of adrenomedullin22-52, CGRP8-37 and BIBN4096BS. | Q42168349 | ||
| Effect of the calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant in human cranial arteries | Q42882636 | ||
| Mice lacking the neuropeptide alpha-calcitonin gene-related peptide are protected against diet-induced obesity | Q42976987 | ||
| Sensitization of calcitonin gene-related peptide receptors by receptor activity-modifying protein-1 in the trigeminal ganglion | Q44367679 | ||
| Innervation of the feline cerebral vasculature by nerve fibers containing calcitonin gene-related peptide: trigeminal origin and co-existence with substance P. | Q44639040 | ||
| Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes | Q45251469 | ||
| Pharmacologic Characterization of AMG 334, a Potent and Selective Human Monoclonal Antibody against the Calcitonin Gene-Related Peptide Receptor | Q46226305 | ||
| International Union of Pharmacology. LXIX. Status of the calcitonin gene-related peptide subtype 2 receptor | Q46541484 | ||
| Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: Results of the Phase 1 program | Q46698001 | ||
| Pharmacology of the human CGRP1 receptor in Cos 7 cells | Q46866643 | ||
| Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study | Q47644533 | ||
| Differentiation of nerve fibers storing CGRP and CGRP receptors in the peripheral trigeminovascular system | Q47747629 | ||
| Safety, tolerability and pharmacokinetics of BIBN 4096 BS, the first selective small molecule calcitonin gene-related peptide receptor antagonist, following single intravenous administration in healthy volunteers | Q47953579 | ||
| CGRP receptor antagonist activity of olcegepant depends on the signalling pathway measured | Q47976301 | ||
| Localization of CGRP receptor components and receptor binding sites in rhesus monkey brainstem: A detailed study using in situ hybridization, immunofluorescence, and autoradiography | Q48113165 | ||
| Localization of binding sites for calcitonin gene-related peptide in rat brain by in vitro autoradiography | Q48271361 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 625-636 | |
| P577 | publication date | 2017-02-24 | |
| P1433 | published in | Headache | Q5689497 |
| P1476 | title | CGRP and its receptors | |
| P478 | volume | 57 |
| Q93024942 | Aberrant expression of calcitonin gene-related peptide and its correlation with prognosis in severe childhood pneumonia |
| Q39293507 | Amylin |
| Q47979735 | CGRP Monoclonal Antibodies for Migraine: Rationale and Progress. |
| Q92337010 | CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP? |
| Q90221947 | CGRP in a gene-environment interaction model for depression: effects of antidepressant treatment |
| Q90321627 | CGRP-based Migraine Therapeutics: How Might They Work, Why So Safe, and What Next? |
| Q89462387 | Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting |
| Q52309667 | Cortical spreading depression as a site of origin for migraine: Role of CGRP. |
| Q89746308 | Dimethyl fumarate alleviates the nitroglycerin (NTG)-induced migraine in mice |
| Q92826157 | Endogenous Neuropeptide Nocistatin Is a Direct Agonist of Acid-Sensing Ion Channels (ASIC1, ASIC2 and ASIC3) |
| Q93170923 | Microbiota and gut neuropeptides: a dual action of antimicrobial activity and neuroimmune response |
| Q90700664 | Molecular Signature for Receptor Engagement in the Metabolic Peptide Hormone Amylin |
| Q101121171 | Optimal treatment strategy of fremanezumab in migraine prevention: a systematic review with network meta-analysis of randomized clinical trials |
| Q89562323 | Peripherally administered calcitonin gene-related peptide induces spontaneous pain in mice: implications for migraine |
| Q97517034 | Role of Calcitonin Gene-Related Peptide in Nociceptive Modulationin Anterior Cingulate Cortex of Naïve Rats and Rats With Inflammatory Pain |
| Q48054533 | Role of calcitonin gene-related peptide in energy metabolism. |
| Q96304876 | The role of erenumab in the treatment of migraine |
| Q42706186 | Triptans and CGRP blockade - impact on the cranial vasculature |
| Q46277281 | Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR Review 25. |
Search more.